{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:13:26Z","timestamp":1792725206577,"version":"4.5.0"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>\n                    Leishmaniasis is a group of neglected tropical diseases caused by protozoan parasites of the genus\n                    <jats:italic>Leishmania<\/jats:italic>\n                    , transmitted by the bite of infected female phlebotomine sandflies. Manifesting as cutaneous (CL), mucocutaneous (MCL), and visceral (VL) forms, it remains a major global health burden, affecting millions in tropical and subtropical regions, with an estimated 30,000 new VL cases annually and over 1 billion people at risk. The disease is defined not only by the parasite but by the host immune response: protective Th1-mediated cellular immunity, characterized by IFN-\u03b3, TNF-\u03b1, IL-12, and nitric oxide production, is essential for parasite clearance, while Th2 skewing, IL-10 dominance, and immune anergy permit progressive disease. Current chemotherapy relies on a limited and problematic drug arsenal. Pentavalent antimonials face widespread resistance, particularly in the Indian subcontinent. Amphotericin B achieves high cure rates but demands hospitalization and causes significant nephrotoxicity. Miltefosine, the only oral agent available, achieves 94\u201397% initial cure rates in Indian VL (Bihar region) but is complicated by teratogenicity, gastrointestinal toxicity, 10\u201320% relapse rates, and emerging resistance. No licensed vaccine exists for human leishmaniasis. This narrative review synthesizes current understanding of\n                    <jats:italic>Leishmania<\/jats:italic>\n                    pathogenesis and host immunity, evaluates the treatment landscape across drug classes, and critically examines immunotherapy and immunochemotherapy strategies, including cytokine-based approaches, TLR agonists, therapeutic vaccines, and novel platforms such as\n                    <jats:italic>\u03b1<\/jats:italic>\n                    -Gal epitope-targeted virus-like particles (VLPs), as strategies to restore protective immunity and address the limitations of chemotherapy alone. We also assess mucosal vaccination as an underexplored delivery route with documented advantages for Th1 polarization and tissue-resident memory induction. Together, these approaches point toward a future of combination immunochemotherapy capable of achieving durable cure, preventing relapse and post-kala-azar dermal leishmaniasis (PKDL), and overcoming drug resistance across clinical forms of leishmaniasis.\n                  <\/jats:p>","DOI":"10.3389\/fmicb.2026.1861933","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:56:20Z","timestamp":1782280580000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Leishmaniasis: pathogenesis, host immunity, and the evolving landscape of immunotherapy and immunochemotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Godspower N.","family":"Okeke","sequence":"first","affiliation":[{"name":"Department of Biological Sciences, University of Southern Mississippi","place":["Hattiesburg, MS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugochukwu K.","family":"Oduwe","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of Southern Mississippi","place":["Hattiesburg, MS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgi","family":"Kenkebashvili","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of Southern Mississippi","place":["Hattiesburg, MS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shefa","family":"Tabassum","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of Southern Mississippi","place":["Hattiesburg, MS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre F.","family":"Marques","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of Southern Mississippi","place":["Hattiesburg, MS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fimmu.2012.00080","article-title":"T Helper1\/T Helper2 cells and resistance\/susceptibility to Leishmania infection: is this paradigm still relevant?","volume":"3","author":"Alexander","year":"2012","journal-title":"Front. Immunol."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.4049\/jimmunol.146.7.2394","article-title":"Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-alpha-galactosyl antibodies","volume":"146","author":"Almeida","year":"1991","journal-title":"J. Immunol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3390\/pathogens13090812","article-title":"Advances in Leishmania vaccines: current development and future prospects","volume":"13","author":"Ayala","year":"2024","journal-title":"Pathogens"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/infdis\/154.6.1003","article-title":"New perspectives on a subclinical form of visceral leishmaniasis","volume":"154","author":"Badaro","year":"1986","journal-title":"J. Infect. Dis."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/bmb\/lds031","article-title":"Management of trypanosomiasis and leishmaniasis","volume":"104","author":"Barrett","year":"2012","journal-title":"Br. Med. Bull."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4269\/ajtmh.14-0743","article-title":"Amphotericin B formulations and other drugs for visceral leishmaniasis","volume":"92","author":"Berman","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e1657","DOI":"10.1371\/journal.pntd.0001657","article-title":"Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis","volume":"6","author":"Bhandari","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1086\/380638","article-title":"Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India","volume":"38","author":"Bhattacharya","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1573618","DOI":"10.3389\/fmolb.2025.1573618","article-title":"Unravelling drug resistance in leishmaniasis: genomic adaptations and emerging therapies","volume":"12","author":"Bhusal","year":"2025","journal-title":"Front. Mol. Biosci."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"ref12","first-page":"606526","article-title":"The bone marrow: an additional site for Leishmania major establishment and maintenance","volume":"11","author":"Carneiro","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref13","first-page":"e0012229","article-title":"Heterologous vaccine therapy associated with half course of miltefosine achieves sterile cure in a hamster model of visceral leishmaniasis","volume":"16","author":"Carvalho","year":"2022","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4103\/0974-777X.62887","article-title":"Drug resistance in leishmaniasis","volume":"2","author":"Chakravarty","year":"2010","journal-title":"J Glob Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/DDDT.S16381","article-title":"Drug discovery and development for neglected diseases: the DNDi model","volume":"5","author":"Chatelain","year":"2011","journal-title":"Drug Des. Devel. Ther."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1128\/IAI.00394-07","article-title":"Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells","volume":"75","author":"Coler","year":"2007","journal-title":"Infect. Immun."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fimmu.2013.00185","article-title":"Multi-faceted functions of secretory IgA at mucosal surfaces","volume":"4","author":"Corth\u00e9sy","year":"2013","journal-title":"Front. Immunol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e0003594","DOI":"10.1371\/journal.pntd.0003439","article-title":"Intranasal vaccination with leishmanial antigens protects golden hamsters (Mesocricetus auratus) against Leishmania (Viannia) braziliensis infection","volume":"9","author":"da Silva-Couto","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3389\/fimmu.2019.00670","article-title":"Cytokines: key determinants of resistance or disease progression in visceral leishmaniasis","volume":"10","author":"Dayakar","year":"2019","journal-title":"Front. Immunol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/1756-3305-7-448","article-title":"Intranasal vaccination with extracellular serine proteases of Leishmania amazonensis confers protective immunity to BALB\/c mice against infection","volume":"7","author":"de Matos Guedes","year":"2014","journal-title":"Parasit. Vectors"},{"key":"ref22","first-page":"1","article-title":"The dialogue of the host-parasite relationship: Leishmania spp. and Trypanosoma cruzi Infection","author":"de Morais","year":"2015"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3389\/fimmu.2017.01779","article-title":"Alternative to chemotherapy: the unmet demand against leishmaniasis","volume":"8","author":"Didwania","year":"2017","journal-title":"Front. Immunol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e0011136","DOI":"10.1371\/journal.pntd.0011136","article-title":"Fexinidazole for visceral leishmaniasis: a phase II\/III trial","volume":"17","year":"2023","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1017\/S0031182097002175","article-title":"Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG","volume":"116","author":"Dube","year":"1998","journal-title":"Parasitology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/j.vaccine.2016.04.067","article-title":"Strategic evaluation of vaccine candidate antigens for the prevention of visceral Leishmaniasis","volume":"34","author":"Duthie","year":"2016","journal-title":"Vaccine"},{"key":"ref28","first-page":"476","article-title":"Macrophages, pathology and the immune response to Trypanosoma cruzi and Leishmania species infection","volume":"16","author":"Engwerda","year":"2004","journal-title":"Curr. Opin. Immunol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e2914","DOI":"10.1371\/journal.pntd.0002914","article-title":"Immune regulation during chronic visceral leishmaniasis","volume":"8","author":"Faleiro","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/fimmu.2019.00916","article-title":"Nanoemulsion adjuvant augments retinaldehyde dehydrogenase activity in dendritic cells via MyD88 pathway","volume":"10","author":"Farazuddin","year":"2019","journal-title":"Front. Immunol."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1089\/ten.teb.2014.0392","article-title":"Avoiding detrimental human immune response against mammalian extracellular matrix implants","volume":"21","author":"Galili","year":"2015","journal-title":"Tissue Eng. Part B Rev."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"6487","DOI":"10.1016\/j.vaccine.2020.08.032","article-title":"Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present alpha-gal epitopes","volume":"38","author":"Galili","year":"2020","journal-title":"Vaccine"},{"key":"ref33","first-page":"31","article-title":"The evolutionary appearance of alpha-gal epitopes in bacteria, parasites, and humans","volume":"96","author":"Galili","year":"2021","journal-title":"Subcell. Biochem."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1084\/jem.162.2.573","article-title":"Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1-3)-linked galactose residues","volume":"162","author":"Galili","year":"1985","journal-title":"J. Exp. Med."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e1974","DOI":"10.1371\/journal.pntd.0001974","article-title":"Leishmania donovani develops resistance to drug combinations","volume":"6","author":"Garcia-Hernandez","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1016\/j.vaccine.2015.12.071","article-title":"Status of vaccine research and development of vaccines for leishmaniasis","volume":"34","author":"Gillespie","year":"2016","journal-title":"Vaccine"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3389\/fcimb.2019.00427","article-title":"An overview of immunotherapeutic approaches against canine visceral leishmaniasis","volume":"9","author":"Gon\u00e7alves","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1016\/j.vaccine.2007.08.001","article-title":"Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant","volume":"25","author":"Goto","year":"2007","journal-title":"Vaccine"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e709","DOI":"10.1371\/journal.pntd.0000709","article-title":"Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial","volume":"4","author":"Hailu","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"571242","DOI":"10.4061\/2011\/571242","article-title":"Use of antimony in the treatment of leishmaniasis: current status and future directions","volume":"2011","author":"Haldar","year":"2011","journal-title":"Mol. Biol. Int."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.pt.2016.11.003","article-title":"Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs","volume":"33","author":"Hefnawy","year":"2017","journal-title":"Trends Parasitol."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e0009627","DOI":"10.1371\/journal.pntd.0009627","article-title":"Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis","volume":"15","author":"Helou","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1038\/nm1213","article-title":"Mucosal immunity and vaccines","volume":"11","author":"Holmgren","year":"2005","journal-title":"Nat. Med."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/pathogens14121202","article-title":"Immunotherapeutics combining a recombinant chimeric protein, monophosphoryl lipid A, and miltefosine against visceral leishmaniasis","volume":"14","author":"Jesus","year":"2025","journal-title":"Pathogens"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1056\/NEJM199912093412403","article-title":"Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis","volume":"341","author":"Jha","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrmicro2608","article-title":"Leishmaniasis: complexity at the host-pathogen interface","volume":"9","author":"Kaye","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.22207\/JPAM.12.4.10","article-title":"Adjunct therapy of rIFN-gamma and rIL-17A along with sub-optimal dose of amphotericin-B effectively controls the Leishmania donovani parasitic growth in infected mice","volume":"12","author":"Kumar","year":"2018","journal-title":"J. Pure Appl. Microbiol."},{"key":"ref48","first-page":"14","article-title":"Prophylactic interferon-gamma and interleukin-17 facilitate parasite clearance in experimental visceral leishmaniasis","volume":"9","author":"Kumar","year":"2019","journal-title":"Trop. Parasitol."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines: fortifying the frontiers","volume":"22","author":"Lavelle","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1472-6750-12-7","article-title":"M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses","volume":"12","author":"Lo","year":"2012","journal-title":"BMC Biotechnol."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent progress in mucosal vaccine development: potential and limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref52","first-page":"e006042","article-title":"IL-12 immunotherapy revisited: biology and therapeutic implications for cancer and infection","volume":"11","author":"Masic","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1590\/S0037-86822006000100003","article-title":"Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment","volume":"39","author":"Mayrink","year":"2006","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.vaccine.2008.01.026","article-title":"Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate and the recombinant Leish-110f+MPL-SE vaccine to treat canine visceral leishmaniasis","volume":"26","author":"Miret","year":"2008","journal-title":"Vaccine"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1021\/jacsau.1c00201","article-title":"Reversed immunoglycomics identifies \u03b1-galactosyl-bearing glycotopes specific for Leishmania major Infection","volume":"1","author":"Montoya","year":"2021","journal-title":"JACS Au"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1021\/acscentsci.7b00311","article-title":"Virus-like particle display of the alpha-gal carbohydrate for vaccination against Leishmania infection","volume":"3","author":"Moura","year":"2017","journal-title":"ACS Cent. Sci."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1086\/516482","article-title":"Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis","volume":"175","author":"Murray","year":"1997","journal-title":"J. Infect. Dis."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(05)67629-5","article-title":"Advances in leishmaniasis","volume":"366","author":"Murray","year":"2005","journal-title":"Lancet"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.trstmh.2007.08.006","article-title":"Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment","volume":"102","author":"Musa","year":"2008","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S1674-8301(10)60004-8","article-title":"A review of adjuvants for Leishmania vaccine candidates","volume":"24","author":"Mutiso","year":"2010","journal-title":"J. Biomed. Res."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of bell's palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"284","DOI":"10.26719\/1997.3.2.284","article-title":"The experience of leishmanization in the Islamic Republic of Iran","volume":"3","author":"Nadim","year":"2014","journal-title":"East Mediterr. Health J."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.1016\/j.vaccine.2008.09.085","article-title":"First generation leishmaniasis vaccines: a review of field efficacy trials","volume":"26","author":"Noazin","year":"2008","journal-title":"Vaccine"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1128\/CMR.18.2.293-305.2005","article-title":"Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view","volume":"18","author":"Olivier","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fimmu.2020.00204","article-title":"The delay in the licensing of protozoal vaccines: a comparative history","volume":"11","author":"Palatnik-de-Sousa","year":"2020","journal-title":"Front. Immunol."},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.09.1248","article-title":"Exploring sand fly salivary proteins to design multiepitope subunit vaccine to fight against visceral leishmaniasis","author":"Pandey","year":"2020","journal-title":"Int J Infect Dis."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"e0006052","DOI":"10.1371\/journal.pntd.0006052","article-title":"Drug resistance and treatment failure in leishmaniasis: a 21st century challenge","volume":"11","author":"Ponte-Sucre","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"e09134","DOI":"10.1016\/j.heliyon.2022.e09868","article-title":"Activation of TLR-pathway to induce host Th1 immune response against visceral leishmaniasis: involvement of galactosylated-flavonoids","volume":"8","author":"Pradhan","year":"2022","journal-title":"Heliyon"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s13071-016-1822-9","article-title":"Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl\/6 mice","volume":"9","author":"Pratti","year":"2016","journal-title":"Parasit. Vectors"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"e0007564","DOI":"10.1371\/journal.pntd.0007146","article-title":"The role of TLR9 on Leishmania amazonensis infection and its influence on intranasal LaAg vaccine efficacy","volume":"13","author":"Pratti","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/cid\/cit102","article-title":"Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, re-infection, or non-compliance","volume":"56","author":"Rijal","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3389\/fimmu.2014.00272","article-title":"Immunotherapy and immunochemotherapy in visceral leishmaniasis: promising treatments for this neglected disease","volume":"5","author":"Roatt","year":"2014","journal-title":"Front. Immunol."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13071-016-1412-x","article-title":"Regulation of immunity during visceral Leishmania infection","volume":"9","author":"Rodrigues","year":"2016","journal-title":"Parasit. Vectors"},{"key":"ref73","first-page":"6011","article-title":"Current trends in drug synthesis for the treatment of leishmaniasis","volume":"19","author":"Roussaki","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nri933","article-title":"The immunology of susceptibility and resistance to Leishmania major in mice","volume":"2","author":"Sacks","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"ref75","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3855\/jidc.6833","article-title":"Recent updates and perspectives on leishmaniasis","volume":"9","author":"Savoia","year":"2015","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nri.2016.72","article-title":"Cutaneous leishmaniasis: immune responses in protection and pathogenesis","volume":"16","author":"Scott","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fimmu.2020.00171","article-title":"The TLR5 agonist flagellin shapes phenotypical and functional activation of lung mucosal antigen presenting cells in neonatal mice","volume":"11","author":"Sharma","year":"2020","journal-title":"Front. Immunol."},{"key":"ref78","doi-asserted-by":"publisher","first-page":"e85530","DOI":"10.1371\/journal.pone.0094596","article-title":"Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis","volume":"9","author":"Shivahare","year":"2014","journal-title":"PLoS One"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S1995-7645(12)60084-4","article-title":"Leishmaniasis: current status of available drugs and new potential drug targets","volume":"5","author":"Singh","year":"2012","journal-title":"Asian Pac J Trop Med"},{"key":"ref80","first-page":"1007199","article-title":"Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects","volume":"14","author":"Singh","year":"2023","journal-title":"Front. Immunol."},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1017\/S0031182018000860","article-title":"Anti-alpha-gal antibodies detected by novel neoglycoproteins as a diagnostic tool for Old World cutaneous leishmaniasis caused by Leishmania major","volume":"145","author":"Subramaniam","year":"2018","journal-title":"Parasitology"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1517\/14656566.2013.755515","article-title":"Leishmaniasis: an update of current pharmacotherapy","volume":"14","author":"Sundar","year":"2013","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref83","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.trstmh.2006.02.011","article-title":"Oral miltefosine for the treatment of Indian visceral leishmaniasis","volume":"100","author":"Sundar","year":"2006","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1086\/380971","article-title":"Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations","volume":"38","author":"Sundar","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref85","first-page":"733","article-title":"Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management","volume":"3","author":"Sundar","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"e0046824","DOI":"10.1128\/iai.00323-25","article-title":"Dual immunomodulatory and antileishmanial potential of TLR7\/8 agonists against Leishmania donovani","volume":"93","author":"Thakur","year":"2025","journal-title":"Infect. Immun."},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3389\/fimmu.2019.00227","article-title":"Molecular aspects of dendritic cell activation in leishmaniasis: an immunobiological view","volume":"10","author":"Tib\u00farcio","year":"2019","journal-title":"Front. Immunol."},{"key":"ref88","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/biology12060851","article-title":"Efficacy of an immunotherapy combining immunogenic chimeric protein plus adjuvant and amphotericin B against murine visceral leishmaniasis","volume":"12","author":"Vale","year":"2023","journal-title":"Biology"},{"key":"ref89","volume-title":"Leishmaniasis Fact Sheet","year":"2024"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1096458","DOI":"10.3389\/fmed.2023.1096458","article-title":"Immunotherapy and immunochemotherapy in combating visceral leishmaniasis","volume":"10","author":"Yadagiri","year":"2023","journal-title":"Front. Med."},{"key":"ref91","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1038\/s41467-020-17154-z","article-title":"A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref92","doi-asserted-by":"publisher","first-page":"e0012783","DOI":"10.1371\/journal.pntd.0012735","article-title":"Progress in antileishmanial drugs: mechanisms, challenges, and prospects","volume":"19","author":"Zhang","year":"2025","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref94","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s13071-016-1721-0","article-title":"The immunology of post-kala-azar dermal leishmaniasis (PKDL)","volume":"9","author":"Zijlstra","year":"2016","journal-title":"Parasit. Vectors"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1861933\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:56:23Z","timestamp":1782280583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1861933\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":94,"alternative-id":["10.3389\/fmicb.2026.1861933"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1861933","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"1861933"}}